AMIDEBIO
AmideBio, LLC, a biotechnology company, focuses on the development, production, and commercialization of peptide research reagents and clinical products for research and development, clinical, and therapeutic marketplaces.
AMIDEBIO
Industry:
Biotechnology Health Care Therapeutics
Founded:
2009-01-01
Address:
Louisville, Colorado, United States
Country:
United States
Website Url:
http://www.AmideBio.com
Total Employee:
1+
Status:
Active
Contact:
303 604 0296
Email Addresses:
[email protected]
Total Funding:
2.59 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Sitelinks Search Box
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.AmideBio.com
- Host name: 143.198.146.38
- IP address: 143.198.146.38
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "AmideBio"
Home | Amidebio | Novel Peptides Targeting Metabolic …
AmideBio is leveraging its in-silico design and proprietary peptide synthesis capabilities to develop a pipeline of unique peptide drug candidates targeting some of the biggest therapeutic challenges for metabolic disease. In addition, …See details»
About | Amidebio | Novel Peptides Targeting Metabolic Disease
AmideBio was founded in 2009 to commercialize the proprietary BioPure platform technology to deliver difficult-to-manufacture, ultrapure peptides to the biopharmaceutical industry and …See details»
AmideBio - Crunchbase Company Profile & Funding
AmideBio, LLC, a biotechnology company, focuses on the development, production, and commercialization of peptide research reagents and clinical products for research and …See details»
amidebio.com Reviews: Is this site a scam or legit?
Organization Proxy Protection LLC . Owner Proxy Protection LLC . Address 417 Associated Rd #327 C/O amidebio.com . State CA . Country UNITED STATES . Country Code US . ...See details»
AmideBio Company Profile 2024: Valuation, Funding
AmideBio General Information Description. Operator of a biotechnology company intended to develop peptide therapeutics for metabolic disease The company's platform develops and commercializes peptide research reagents and clinical …See details»
AmideBio - Products, Competitors, Financials, Employees, …
About AmideBio. AmideBio focuses on the development of novel peptides for the treatment of metabolic diseases within the biotechnology sector. The company leverages in-silico design …See details»
AmideBio Company Profile - Office Locations, Competitors ... - Craft
AmideBio has 5 employees across 2 locations and $2.59 m in total funding,. See insights on AmideBio including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
AmideBio, LLC Company Profile | Louisville, CO | Competitors ...
Find company research, competitor information, contact details & financial data for AmideBio, LLC of Louisville, CO. Get the latest business insights from Dun & Bradstreet.See details»
AmideBio - Funding, Financials, Valuation & Investors - Crunchbase
Organization. AmideBio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Funding Rounds 8. obfuscated. ... AmideBio …See details»
AmideBio - Contacts, Employees, Board Members, Advisors
Organization. AmideBio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... AmideBio has 1 board member or advisor, …See details»
AmideBio Awarded SBIR Phase IIB Grant to Support Pre-Clinical ...
BOULDER, CO, October 4th, 2022 – AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $2.69M in funding through a Phase IIB Small …See details»
Boulder’s AmideBio wins SBIR grant for diabetes treatment research
Sep 16, 2024 BOULDER — Biopharmaceutical company AmideBio LLC has received a $1.93 million grant from the federal government for diabetes treatment research. Small Business …See details»
AmideBio Awarded SBIR Phase IIB Grant to Support Pre-Clinical ...
Oct 4, 2022 AmideBio has a pipeline of novel biotherapeutics targeting metabolic diseases. This pipeline was generated by leveraging its core competencies in intelligent design of drug …See details»
AMIDEBIO, LLC: U.S. FDA grants rare pediatric disease designation …
Aug 23, 2020 AmideBio, LLC issued the following announcement on August 20. AmideBio, LLC, a privately held biopharmaceutical company, announced that the US Food and Drug …See details»
U.S. FDA grants rare pediatric disease designation to AmideBio's ...
BOULDER, Colo., Aug. 20, 2020 /PRNewswire/ -- AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration …See details»
AmideBio Awarded SBIR Phase II Grant to Further Development of …
BOULDER, CO, September 30, 2019 – AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $1.56M in funding through a Phase II Small …See details»
News | Amidebio | Novel Peptides Targeting Metabolic Disease
Sep 3, 2018 BOULDER, CO, March 8, 2021 – AmideBio, LLC, a privately-held biopharmaceutical company, announced today that it has received $300,000 in funding …See details»
Novel Peptides Targeting Metabolic Disease - Amidebio
AmideBio’s lead program is the development of novel glucose responsive insulins (GRIs) that will eliminate the need for basal and prandial insulins through a single weekly dose. These novel …See details»
Glucose responsive insulin - AmideBio - AdisInsight - Springer
Glucose sensing insulin designated as AB GSI 084, is being developed by AmideBio for the treatment of type 1 and type-2 diabetes mellitus. AB-GSI 084 is based Glucose responsive …See details»
Novel Peptides Targeting Metabolic Disease - Amidebio
AmideBio has built a catalog of peptides using its BioPure process ensuring unequaled purity and lack of contaminating side and by-products. While other manufacturers strive to achieve 97% …See details»